Diversity, Equity and Inclusion:
As members of PhRMA, we believe improving human life means celebrating human diversity
Inclusion and Diversity at Teva
At Teva, everyone belongs and all opinions are valued. We welcome and appreciate individuals of all ethnicities, races, religions, cultures, culture identities, sexual orientations, ages, abilities and opinions.
When our people are heard, respected and empowered, they are able to be their best selves, realize their full potential and apply their skills and talents. This strengthens our organization, fueling our creativity and innovation as we work to improve health for people of all backgrounds.
Increasing Gender Equality
We continue to improve gender equality in our workforce. In 2021, our external hires represented a 50/50 men/women distribution for management roles. This reflected an increase in gender equality in executive and senior management positions by 1.8% between 2020 and 2021 and the number of women successors for critical positions at the Vice President level and above.
Pay Equity
We aim for pay equity at all levels. In 2021, Teva conducted comprehensive equitable pay research among 100% of our employees, which compared each employee and an equivalent colleague with the same profile and location. The findings revealed that among those in the same level, function/profession and location, Teva pays women 1% more than men for base salaries.
Teva also calculated mean payments of women compared to men, without considering level, function/profession and location. In this context, due to the influence of worldwide workforce demographics, the mean base salaries for men were 3% more than the base salaries for women. This gap is significantly ahead of the gap identified by Bloomberg Gender-Equality Index members, which shows men receive on average 21% more than women.
Environmental Sustainability:
As members of PhRMA, we believe a healthy environment is essential for improving human life
Climate Action and Resilience
In 2021, we reevaluated our climate targets and published new, more ambitious targets that we have committed to have validated by the Science Based Targets initiative (SBTi). These include reducing our scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and by 46% by 2030. We also committed to reducing scope 3 GHG emissions by 25% by 2030. In 2021, we reported our full scope 3 emissions for the first time, reflecting our efforts to increase transparency and measure reductions in GHG emissions across our value chain.
Assessing the Lifecycle of Products
In 2021, in line with our goal to assess the environmental lifecycle of key products—and in response to questions from customers—we performed an assessment of one of our migraine products. Our findings indicated the electricity used in drug substance production is the main contributor to its carbon and water footprint, and end-consumers’ trips to the pharmacy to pick up their prescription was also significant to the total carbon footprint. The assessment suggests there is opportunity to work with drug substance manufacturers to reduce electricity consumption or use renewable energy and optimize the delivery chain to reduce cold storage.
Reducing Paper Waste
Teva US began implementing electronic medication guides for products in 2021, replacing the previous paper leaflets. This will significantly reduce the amount of paper used in Teva’s packaging operations by 3,000 tons, equivalent to 72,000 trees, once the project is complete at the end of 2022.
Integrating ESG into business strategy
In 2021, we issued a $5 billion sustainability-linked bond (SLB)—the first linked to both access to medicines and environmental targets. The environmental goal of the SLB is to reduce absolute scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 (vs. 2019)
Effluents and Waste
We are actively addressing waste minimization and management through our Sustainability Task Force, which includes a workstream on waste that aims to identify waste reduction opportunities. For example, we incorporate chemistry design principles during the product R&D phase, which can have a significant impact on reducing waste by design and improving effluent discharges when scaled-up to manufacturing at our production facilities. In addition to the efforts at our operations sites, our green office program is being rolled out across the world, which includes initiatives to reduce waste and introduce recycling schemes.
Access & Affordability:
As members of PhRMA, we believe that living our mission of improving human life relies on broad access to medicines
Expanding Access to Medicines Program
We committed to launch eight access to medicines programs by 2025 and launched four of these programs by early 2022. We also donated $487 million worth of medicines (307 million units) to patients in need in 2021, including 219 million doses in the US.
Advancing Access to Behavioral Health Services
In June 2022, Teva launched its fifth access program – a new initiative in the US partnering with Direct Relief and NAFC to expand medication access and provide grant funding to free and charitable clinics that care for medically underserved patients suffering from depression and/or anxiety. The pilot program –initially in Florida, New Jersey and California – aims to help advance health equity for underserved populations. Initial grant funding to 11 free and charitable clinics was announced in October 2022.
Being a Trusted Partner During Emergencies and Disasters
When Hurricane Ida, one of the most powerful and rapidly intensifying storms hit the US, Teva responded swiftly and distributed $46 million worth of products across Louisiana and Texas through our partnership with Direct Relief.
Supporting Humanitarian Efforts for Ukrainian Refugees
In 2022, Teva has donated essential medicines valued at more than $11 million for acute therapies to support humanitarian efforts for Ukrainian refugees.
Integrating ESG into business strategy
In 2021, we issued a $5 billion sustainability-linked bond (SLB)—the first linked to both access to medicines and environmental targets. The access goals of the SLB are as follows:
• Increase the cumulative number of new regulatory submissions (2022–2025) in low- and middle-income countries (LMICs) on the World Health Organization’s Essential Medicines List across six key therapeutic areas by 150% by 2025 (vs. 2017–2020)
• Increase access to medicines program product volume by 150% in 2025 (vs. 2020) through four access to medicines programs, including donations and social business, in LMICs on the WHO EML across six key TAs
Advancing Access to Medicines
Teva supports nearly 200 million patients every day with a portfolio of over 2700 generic products including many that are on the WHO Essential Medicines List. In 2020, generic products helped patients and healthcare systems save more than $40 billion.
Our Global Health Economics and Outcomes Research team’s analyses allow us to estimate unmet economic, clinical and quality of life needs, define clinical endpoints and identify appropriate patient populations.